ALX Oncology
ALXO
93 hedge funds and large institutions have $688M invested in ALX Oncology in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 14 closing their positions.
330% more capital invested
Capital invested by funds: $160M → $688M (+$528M)
222% more call options, than puts
Call options by funds: $4.14M | Put options by funds: $1.29M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
106% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 16
22% more funds holding
Funds holding: 76 → 93 (+17)
11.81% more ownership
Funds ownership: 80.88% → 92.69% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$22.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$12M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.8M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$520K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$453K |
| 5 |
Goldman Sachs
New York
|
-$383K |
ALXO Hedge Fund Activity: Q4 2023 in Review
93 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2023, worth a combined $688M — up 330% from $160M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ALXO positions and 14 closed out — a net gain of 18 holders — while 33 added to existing stakes and 16 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $24M. The largest seller was Braidwell, exiting entirely with an estimated $6M sold.
- 93 institutional investors held ALX Oncology (ALXO) as of Q4 2023, up from 76 in Q3 2023.
- Funds reported $688M of ALX Oncology stock for Q4 2023, up 330% quarter-over-quarter.
- 32 funds opened new ALX Oncology positions in Q4 2023 and 14 closed out, a net change of +18 holders.
- The largest ALX Oncology buyer in Q4 2023 was Cormorant Asset Management, an estimated $24M added.
- The largest ALX Oncology seller in Q4 2023 was Braidwell, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2023.